Sparingvision

Treatment for hereditary blindness

Total raised

€135M

€135,000,000

Funding rounds

Investors

distinct backers

Active since

2017-07

latest 2022-09

Funding by year

EUR raised per year

High confidence

Raise-next likelihood39

base rate 48% for Series B

Exit likelihood24

base rate 12% (2+ rounds)

Timing: overdue vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.

3 rounds

Date	Stage	Amount	Investors
2022-09-14	Series B	€75M	4BIO Capital,Bpifrance,Jeito Capital,RD Fund,UPMC Enterprises,Ysios Capital	View deal →
2020-10-21	Other	€45M	4BIO Capital,UPMC Enterprises	View deal →
2017-07-07	Other	€16M	Bpifrance,Fondation Fighting Blindness Clinical Research Institute	View deal →

same sector or country